Lupus Nephritis study results boosted a biopharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, November 16, 2016 (as of 4 pm EST):
Biopharma stock Aurinia Pharmaceuticals Inc. (TSE:AUP) shot up as much as 26% before closing up to 5% to $5.44 on Wednesday after the Company highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of Lupus Nephritis, which Aurinia said successfully achieved higher complete remission rates and more rapidly in patients with Lupus Nephritis.
As well, shares of OrganiGram Holdings Inc. (CVE:OGI) gained as much as 17% before falling 11% on the day as the medical marijuana producer said that construction has begun on its fully-funded expansion, which is expected to be completed and operational in the fall of 2017. The expansion is designed to increase total production capacity to approximately 17,235 kg per year of flower, which would support more than $100 million in annual flower sales.
War Eagle Mining Company Inc. (CVE:WAR), meanwhile, reported that it has swung to a Q2 profit of $2.3 million from a loss of $267,000 during the same period last year, due to a recognized $2.4 gain on the sale of its subsidiary, Tres Marias, a zinc-lead-germanium project in Mexico. War Eagle Mining stock moved up 120% to $0.055 following the announcement.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Biopharma stock Aurinia Pharmaceuticals Inc. (TSE:AUP) shot up as much as 26% before closing up to 5% to $5.44 on Wednesday after the Company highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of Lupus Nephritis, which Aurinia said successfully achieved higher complete remission rates and more rapidly in patients with Lupus Nephritis.
